Unsurprisingly, cohorts within the high-risk group of the three-PSMs model exhibited a significantly greater burden of multiple adverse prognostic factors in AML (Supplementary Table S4), including mutations in TP53, RUNX1, U2AF1, and SRSF2, as well as cytogenetic abnormalities such as -5/5q-, trisomy 8, -7/7q-, and complex karyotype [68]. This evidence concerns the gene TP53 and acute myeloid leukemia.